Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma

Aplidin ® is an antitumour drug, currently undergoing phase II evaluation in different haematological and solid tumours. In this study, we analysed the antimyeloma effects of Aplidin in the syngeneic 5T33MM model, which is representable for the human disease. In vitro , Aplidin inhibited 5T33MMvv DNA synthesis with an IC 50 of 3.87 n M . On cell-cycle progression, the drug induced an arrest in transition from G0/G1 to S phase, while Western blot showed a decreased cyclin D1 and CDK4 expression. Furthermore, Aplidin induced apoptosis by lowering the mitochondrial membrane potential, by inducing cytochrome c release and by activating caspase-9 and caspase-3. For the in vivo experiment, 5T33MM-injected C57Bl/KaLwRij mice were intraperitoneally treated with vehicle or Aplidin (90 μ g kg −1 daily). Chronic treatment with Aplidin was well tolerated and reduced serum paraprotein concentration by 42% ( P